1. Study identification
EU PAS Register NumberEUPAS25523
Official titleBendroflumethiazide versus Indapamide for Primary Hypertension: Observational (BISON) study within CPRD
Study title acronymBISON
Study typeObservational study
Brief description of the studyThis study aims to compare the effects of prescribing indapamide, a thiazide-like diuretic, with bendroflumethiazide, a thiazide diuretic, as the first-line choice of diuretic in the treatment of hypertension. The outcome measure will be a composite of non-fatal myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure or death from cardiovascular causes. We will identify in CPRD all patients aged 18 years and over with first diagnosis of hypertension after 1987. Among them, we will form two groups with first ever prescription of indapamide or bendroflumethiazide. We will follow the groups either to the date of last prescription, date of medication switch, date of additional medication for hypertension (such as beta-blockers, calcium channel blockers, ACE inhibitors, alpha-blockers, ARBs or other antihypertensive medication), date of outcome, date of de-registration with the medical practice or the date of last practice data collection. We will also extract information on patient age, sex, medical practice, co-morbidities, co-prescribed medication, smoking, weight and alcohol consumption. Incidence of event rates will be calculated in each group. Descriptive analysis, and univariate and multivariate Cox regression survival models will be used as appropriate. Subgroup analyses will be implemented for known risk factors. This large population-based study may provide new evidence on the potential benefit of treating hypertensive patients with indapamide or bendroflumethiazide and may inform future clinical trials.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicableISAC protocol 17_232
https://www.cprd.com/isac/
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsMEMO
Department/Research groupMedicines Monitoring Unit
Organisation/affiliationUniversity of Dundee
Details of (Primary) lead investigator
Title Professor
Last name MacDonald
First name Thomas
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/01/2018
Start date of data collection13/09/2018
Start date of data analysis
Date of interim report, if expected
Date of final study report30/06/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councilsFARR Institute research grant and50
EU funding scheme
OtherMEMO departmental funds50
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name MacDonald
First name Thomas
Address line 1Medicines Monitoring Unit/Hypertension Research Centre
Address line 2Ninewells Hospital & Medical School
Address line 3Level 7
CityDundee
PostcodeDD1 9 SY
CountryUnited Kingdom
Phone number (incl. country code)441382383119
Alternative phone number441382383232
Fax number (incl. country code)441382643204
Public Enquiries
Title Professor
Last name MacDonald
First name Thomas
Address line 1Medicines Monitoring Unit/Hypertension Research Centre
Address line 2Ninewells Hospital & Medical School
Address line 3Level 7
CityDundee
PostcodeDD1 9 SY
CountryUnited Kingdom
Phone number (incl. country code)441382383119
Alternative phone number441382383232
Fax number (incl. country code)441382643204
6. Study drug(s) information
Substance class (ATC Code)C03AA01 (bendroflumethiazide)
Substance class (ATC Code)C03BA11 (indapamide)
7. Medical conditions to be studied
Medical condition(s)Yes
Hypertension
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects200000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Drug utilisation study
Effectiveness evaluation
Primary scope : Effectiveness evaluation
12. Main objective(s)
What is the main objective of the study?
To compare, in an observational study using CPRD data, the effect of bendroflumethiazide versus indapamide on of risk of myocardial infarction (MI), acute coronary syndrome, stroke, acute decompensated heart failure & death from cardiovascular causes, in patients with hypertension.
Are there primary outcomes?Yes
The first occurrence of any event within the composite outcome of myocardial infarction (MI); acute coronary syndrome not resulting in myocardial infarction; stroke; acute decompensated heart failure; death from cardiovascular causes.
Are there secondary outcomes?Yes
The individual components of the primary composite outcome described above; death from any cause; primary outcome or death from any cause.
13. Study design
What is the design of the study?
Cohort study
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
We will analyse time trends in the incidence of hypertension between 1987 and 2015 by sex, age and year of diagnosis. We will describe the antihypertensive therapies prescribed following the diagnosis of hypertension. We will assume that patients were treated with either bendroflumethiazide or indapamide if they received at least two prescriptions for that medication following the diagnosis of hypertension.
We will construct two groups by matching patients on a propensity score, namely the probability of exposure to either indapamide or bendroflumethiazide, estimated from a logistic regression model. Time from the Index date to the outcome will be analysed using Cox proportional hazards model. We will conduct two types of analysis: per protocol primary analysis (considering patients only when they were exposed) and intention to treat sensitivity analysis (follow up until outcome or last follow up irrespective whether treatment was discontinued, switched or intensified).